Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,646 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier.
Carpio C, Bouabdallah R, Ysebaert L, Sancho JM, Salles G, Cordoba R, Pinto A, Gharibo M, Rasco D, Panizo C, Lopez-Martin JA, Santoro A, Salar A, Damian S, Martin A, Verhoef G, Van den Neste E, Wang M, Couto S, Carrancio S, Weng A, Wang X, Schmitz F, Wei X, Hege K, Trotter MWB, Risueño A, Buchholz TJ, Hagner PR, Gandhi AK, Pourdehnad M, Ribrag V. Carpio C, et al. Among authors: pinto a. Blood. 2020 Mar 26;135(13):996-1007. doi: 10.1182/blood.2019002395. Blood. 2020. PMID: 31977002 Free PMC article.
Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas.
Corazzelli G, Frigeri F, Arcamone M, Aloj L, Capobianco G, Becchimanzi C, Morelli E, Volzone F, Marcacci G, Russo F, De Filippi R, Lastoria S, Pinto A. Corazzelli G, et al. Among authors: pinto a. Eur J Haematol. 2011 Dec;87(6):547-53. doi: 10.1111/j.1600-0609.2011.01683.x. Epub 2011 Jul 31. Eur J Haematol. 2011. PMID: 21752099 Free PMC article.
High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
Musso M, Messina G, Marcacci G, Crescimanno A, Console G, Donnarumma D, Scalone R, Pinto A, Martino M. Musso M, et al. Among authors: pinto a. Biol Blood Marrow Transplant. 2015 Nov;21(11):1932-8. doi: 10.1016/j.bbmt.2015.06.011. Epub 2015 Jun 19. Biol Blood Marrow Transplant. 2015. PMID: 26099830 Free article. Clinical Trial.
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.
Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, Zhang H, Offner F, Scheliga A, Nowakowski GS, Pinto A, Re F, Fogliatto LM, Scheinberg P, Flinn IW, Moreira C, Cabeçadas J, Liu D, Kalambakas S, Fustier P, Wu C, Gribben JG; AUGMENT Trial Investigators. Leonard JP, et al. Among authors: pinto a. J Clin Oncol. 2019 May 10;37(14):1188-1199. doi: 10.1200/JCO.19.00010. Epub 2019 Mar 21. J Clin Oncol. 2019. PMID: 30897038 Free PMC article. Clinical Trial.
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma.
Armand P, Janssens A, Gritti G, Radford J, Timmerman J, Pinto A, Mercadal Vilchez S, Johnson P, Cunningham D, Leonard JP, Rodig SJ, Martín-Regueira P, Sumbul A, Samakoglu S, Tang H, Ansell SM. Armand P, et al. Among authors: pinto a. Blood. 2021 Feb 4;137(5):637-645. doi: 10.1182/blood.2019004753. Blood. 2021. PMID: 32870269 Free PMC article. Clinical Trial.
End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA.
Kostakoglu L, Martelli M, Sehn LH, Belada D, Carella AM, Chua N, Gonzalez-Barca E, Hong X, Pinto A, Shi Y, Tatsumi Y, Knapp A, Mattiello F, Nielsen T, Sahin D, Sellam G, Oestergaard MZ, Vitolo U, Trněný M. Kostakoglu L, et al. Among authors: pinto a. Blood Adv. 2021 Mar 9;5(5):1283-1290. doi: 10.1182/bloodadvances.2020002690. Blood Adv. 2021. PMID: 33651099 Free PMC article. Clinical Trial.
Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab.
De Filippi R, Morabito F, Santoro A, Tripepi G, D'Alò F, Rigacci L, Ricci F, Morelli E, Zinzani PL, Pinto A. De Filippi R, et al. Among authors: pinto a. J Transl Med. 2021 Dec 1;19(1):489. doi: 10.1186/s12967-021-03134-4. J Transl Med. 2021. PMID: 34852840 Free PMC article.
4,646 results